Palabras clave
Obesidad
Factores de Riesgo
Comorbilidades
Consecuencias
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Relacionar las consecuencias de COVID-19 con los hallazgos de investigaciones realizadas en pacientes obesos que han sido afectados por la enfermedad. Revisión bibliográfica: La literatura internacional sugiere una relación significativa entre la obesidad y la gravedad de la COVID-19. Realizar investigaciones utilizando protocolos clínicos y epidemiológicos es crucial para establecer de manera más precisa la conexión entre la obesidad y el riesgo de complicaciones de la COVID-19. Estos estudios pueden ayudar a obtener una comprensión más profunda de esta asociación e identificar los factores subyacentes que contribuyen a las complicaciones concurrentes en pacientes con sobrepeso. Consideraciones Finales: La obesidad es una enfermedad crónica no transmisible, representando un factor de riesgo significativo para el agravamiento de la COVID-19. Sin embargo, es esencial destacar que es prevenible. La adopción de hábitos de vida saludables no solo puede mitigar los riesgos asociados con la obesidad, sino que también tiene el potencial de reducir la gravedad de las infecciones por COVID-19, dado que ambas condiciones se caracterizan por procesos inflamatorios.
Referencias
AMARAL LMB, et al. Vias metabólicas e hiperinflamação na COVID 19 em obesos diabéticos renais crônicos e sua reabilitação física pós-infecção / Metabolic pathways and hyperinflammation in COVID 19 in obese and chronic renal diabetic patients and their post-infection physical rehabilitation. Brazilian Journal of Development, 2021; 7: 67591-67615.
APOVIAN CM, et al. Body Weight Considerations in the Management of Type 2 Diabetes. Advances in therapy, 2019; 36(1): 44-58.
ATKINSON RL, et al. Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes, 2005; 29(9): 281-286.
BARROSO WA, et al. Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020; 14: 809-814.
BEZERRA et al. Factors associated with people’s behavior in social isolation during the covid-19 pandemic. Ciência e Saúde Coletiva, 2020; 25: 2411-2421.
BRANDÃO S, et al. Obesidade e risco de COVID-19: grave [livro eletrônico]. Recife, 2020; 1.
BURGOS-MORÓN E, et al. Relationship Between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues. J Clin Med, 2019; 9: 1385.
CAMPOS MR, et al. Carga de doença da COVID-19 e de suas complicações agudas e crônicas: reflexões sobre a mensuração (DALY) e perspectivas no Sistema Único de Saúde. Cadernos de Saúde Pública [online], 2020; 36: 11.
CARNETHON M. The Biggest Health Problem: Obesity. Sci Am, 2019; 1.
DANTZER, et al. Resilience and immunity. Brain BehavImmun, 2018; 74: 28-42.
DIETZ WSC. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring), 2020; 28(6): 1005.
DURÃES SA, et al. Implicações da pandemia da covid-19 nos hábitos alimentares. Revista Unimontes Científica, 2020; 22: 1-20.
GABBRIELLI R e PUGNO NM. The impact of mean body mass index on reported mortality from COVID-19 across 181 countries. Frontiers in public health, 2023; 11: 1106313.
GALLEGO P, et al. Adults with congenital heart disease during the coronavirus disease 2019 (COVID-19) pandemic: are they at risk? Revista, 2020; 73(10): 795-798.
GUO W, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev, 2020; 31: 3319.
HONCE RSS. Impact of obesity on influenza a virus pathogenesis, immune response, and evolution. Front Immunol, 2019; 10: 1071.
KALLIGEROS M, et al. Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity (Silver Spring), 2020; 28(7): 1200-4.
KIRWAN R, et al. Sarcopenia During Covid-19 Lockdown Restritions: Long-Term Health Effects of Short-Term Muscle Loss. Geroscience, 2020; 42(6): 1547-1578.
KRAUSE M, et al. Coronavirus infection (SARS-CoV-2) in obesity and diabetes comorbidities: is heat shock response determinant for the disease complications? Diabetol Metab Syndr, 2020; 16: 12-63.
LIM S, et al. Proper Management of People With Obesity During the COVID-19 Pandemic. J. Obes. Metab. Syndr, 2020; 29(2): 84-98.
LUZI L e RADAELLE MG. Influenza and obesity: its odd relationship and the lessonsfor COVID-19 pandemic. Acta Diabetol, 2020; 57(6): 759-764.
MCMICHAEL TM, et al. Public Health–Seattle and King County, EvergreenHealth, and CDC COVID-19 Investigation Team. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. N Engl J Med, 2020; 382(21): 11.
MICHALAKIS K e ILIAS I. SARS-CoV-2 infection and obesity: common inflammatory and metabolic aspects. Diabetes Metab Syndr, 2020; 14(4): 69-71.
NASI, et al. The role of physical activity in individuals with cardiovascular risk factors: an opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. J Cardiovasc, 2019; 20(10): 631-639.
OLIVEIRA ML, et al. Direct healthcare cost of obesity in Brazil: An application of the cost-of-illness method from the perspective of the public health system in 2011. PLoS One, 2015; 10: 4.
OLIVEROS, et al. The concept of normal weight obesity. Prog Cardiovasc Dis, 2014; 56(4): 426-433.
OXLEY TJ, et al. Large-vessel stroke as apresenting feature of Covid-19 in the young. NEngl J Med, 2020; 382: 60.
PECANHA, et al. Social isolation during the COVID-19 pandemic can increase physical inactivity and the global burden of cardiovascular disease. Am J Physiol Circ Physiol, 2020; 318(6): 1441-1446.
RYAN PM e CAPLICE NM. Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019? Obesity (Silver Spring), 2020; 28(7): 1191-1194.
SALES-PERES SHC, et al. Coronavirus (SARS-CoV-2) and the risk of obesity for critically illness and ICU admitted: Meta-analysis of the epidemiological evidence. Obes Res Clin Pract [online], 2020; 14: 389-397.
SBCBM Sociedade Brasileira de Cirurgia Bariátrica e Metabólica. Obesidade atinge mais de 6,7 milhões de pessoas no Brasil em 2022. SISVAN, 2023; 1-3.
SILVA GM, et al. Obesidade como fator agravante da COVID-19 em adultos hospitalizados: revisão integrativa. Acta Paulista de Enfermagem, 2021; 34.
SONZA, et al. Brazil before and during covid-19 pandemic: Impact on the practice and habits of physical exercise. Acta Biomed, 2021; 92(1):1-10.
STEFAN N, et al. Global pandemics interconnected – obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol, 2021; 1.
TANG, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 2020; 18(4): 844-847.
WORLD HEALTH ORGANIZATION (WHO). Coronavirus disease (COVID-19) Situation Report Region. Data as received by WHO from national authorities by 10:00 CEST, 15 set 2023. Geneva: WHO; 2023; 1.
WU D, et al. Plasma metabolomic and lipidomic alterations associated with COVID-19. Med Rxiv, 2020; 26.
ZHANG C, et al. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol, 2020; 5: 428-30.